Search

Displaying results 1711 - 1720 of 7180 in total
  1. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  2. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  3. Drug

    Tubocurarine

    go.drugbank.com/drugs/DB01199
    ApprovedWithdrawn

    [A216008] Curare is one of the names used to describe plant-derived poisons used by indigenous South Americans to coat the tips of hunting arrows and darts, which were typically derived from plants of … [A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen.

  4. Drug

    Chlorzoxazone

    go.drugbank.com/drugs/DB00356
    Approved

    It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

  5. Drug

    Synthetic Conjugated Estrogens, B

    go.drugbank.com/drugs/DB09318
    Approved

    There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. … yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

  6. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    VIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot.

  7. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138]. … It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer.

  8. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting … Fosnetupitant is the pro-drug form of netupitant [FDA label].

  9. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    [L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.

  10. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.